Objective: To report the long-term follow-up of the first living-donor lobar lung transplantation performed in Latin America.
Introduction
Since 1983, when the Toronto Lung Transplant Group reported the first successful lung transplantation, several advances have consolidated this procedure as a treatment modality for patients with end-stage pulmonary disease. 1 However, the increase in the waiting lists for a new organ was not accompanied by an increase in the number of available donors. One of the alternatives found by the group of University of Southern California led by Vaughn Starnes, directed at a population with difficulties in receiving organs from cadavers (children needing bilateral transplantation), was performing a transplant with lobes from living donors in 1992. 2 Starnes' achievement was followed by that of a group by Hiroshi Date, from Okayama University, which conducted a living-donor lobar transplantation in a patient with ciliary dyskinesia in 1998. 3 donors, our group performed the first living-donor lung transplantation in Latin America, whose report is the aim of the present paper.
Case description
The patient, a 12-year-old boy with advanced pulmonary disease due to obliterative bronchiolitis, was admitted for pre-lung transplant evaluation. On that occasion, he was dependent on oxygen, with a forced expiratory volume in With the experience obtained, the important questioning on the possibility of two lobes providing an equivalent function to that of a lung was answered. When patients who underwent living-donor lobar transplantation were compared with those who received lungs from a cadaveric donor, the increase in total lung capacity up to 12 months after transplantation was similar. 5 However, observing the decrease in carbon monoxide diffusion, this was more significant in the first group, suggesting that the gain in lung function is at the expense of alveolar dilatation. Besides that, the analysis of the experience in adults showed that, although FVC and FEV 1 were lower in the living-donor group from the 1st to the 3rd month after transplantation, these values improved and are equivalent to those of patients who received a lung from a cadaveric donor from the sixth month on. 6 Regarding long-term results, recent studies showed a very encouraging scenario. In the series of Date et al., including 30 patients, hospital survival was 100%, with all patients alive at the moment of publication. 7 It should be highlighted that this series is exceptional, due to the peculiarities of the Japanese population, which has a low incidence of cystic fibrosis and presents pulmonary arterial hypertension and interstitial fibrosis as the main indications for transplantation. As in our case, average ICU and hospital stay tend to be long (23 and 64 days respectively in their study).
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